Kornimate/medical-research-clean huggingface dataset:
ventricular arrhythmias in uremic cardiomyopathy

Conditions: Cardiomyopathy

Summary: there is a certain gene called sarcoplasmic reticulum gene (serca2a), which is found in heart muscle. this gene is also found in blood vessels and skin tissue. when active this gene builds a crucial protein inside the heart muscle called serca2a protein. this is responsible for regulating calcium levels inside your heart muscle. when this gene is not activated, studies have shown that it can lead to abnormal electrical currents in the heart that can lead to death. the investigators are conducting this study to prove that serca2a gene is inactive in patients with kidney disease. scientists found that patient at risk for abnormal electrical currents in the heart can be tested by what they called "microvolt twave alternans." this is a very delicate machine much more sensitive than a regular electrocardiogram that you do at the cardiology office.

this study will test the hypothesis that patients with uremic cardiomyopathy have reduced levels of serca2a protein compared to those with normal kidney function. we propose that such a correlation will provide convincing evidence that these patients,have a defective redistribution in intracellular calcium handling as an explanation for their increase risk in sudden cardiac death an fatal arrhythmias. to achieve our specific aims: 1) we will screen patients with end stage renal disease (esrd) going for certain vascular procedures. 2) obtain an echocardiogram on these patients including only those with isolated diastolic dysfunction or lvh. 3) patients who has diastolic dysfunction or lvh will be assessed for underlying microvolt (twa) 4) vessel and skin tissue on these patients will be collected for serca2a quantification.

Eligibility criteria:
inclusion criteria: * age 18 years or older * patients with stage 5 ckd or esrd and those with normal ckd will be considered as possible candidates if admitted for one of the following vascular procedures * coronary artery bypass grafting, or vascular bypass surgery, or arteriovenous fistula creation, or arteriovenous graft surgery. * the aforementioned patients will be included if they have lvh or diastolic dysfunction and a normal lvef on echocardiogram within one year of their scheduled surgery. exclusion criteria: 1. age less than 18 ; 2. pregnancy; 3. dilated cardiomyopathy; 4. left ventricular ejection fraction (lvef) less than or equal to 50%; 5. patients on digoxin. 6. antiarrhytmic medications; 7. baseline electrolyte abnormalities; 8. atrial fibrillation; 9. bundle branch block

Keywords: ventricular arrythmias serca2a chronic kidney disease microvolt t wave alternans
a registry for adolescent and pediatric participants who received a gilead hepatitis c virus direct acting antiviral (daa) in gilead-sponsored chronic hepatitis c infection trials

Conditions: Hepatitis C Virus Infection

Summary: this registry will enroll adolescent and pediatric participants who received at least one gilead hepatitis c virus (hcv) direct acting antiviral (daa) while participating in a gilead-sponsored chronic hepatitis c clinical trial. the primary objective of this registry is to determine the long-term safety of anti-hcv regimens in the pediatric population. secondary objectives of this registry are to determine whether subsequent detection of hcv rna in participants who relapse following sustained virologic response (svr) represents the re-emergence of pre-existing virus, the development of resistance mutations, or whether it is due to re-infection, and to characterize resistance mutations and the persistence of resistance mutations in pediatric participants who did not achieve svr. once enrolled, participants will be followed for up to 5 years.


Eligibility criteria:
key inclusion criteria: * have previously participated in a gilead-sponsored chronic hepatitis c study as an adolescent or pediatric participant and received at least one gilead hcv direct acting antiviral * parent or legal guardian able to provide written informed consent or individual is able to provide written informed consent prior to any study procedures and willing to comply with study requirements as determined by institutional review board (irb)/independent ethics committee(iec)/local requirements and investigator's discretion. * individual is able to provide written assent, if they have the ability to read and write, as determined by irb/iec/local requirements and investigator's discretion key exclusion criteria: * individual is currently receiving or plans to initiate a new course of hepatitis c therapy including any investigational drug or device during the course of the follow-up registry. * history of clinically-significant illness or any other major medical disorder that may interfere with the individual's follow-up, assessments or compliance with the protocol. note: other protocol defined inclusion/exclusion criteria may apply.
correlation between neck pain and visual disturbances in smartphone users

Conditions: Neck Pain; Visual Disturbances

Summary: the goal of this study is to investigate the correlation between neck pain and visual disturbances in smartphone users.

study design: cross-sectional observational analytical study design conducted on smartphone users 2- subject selection 141 subjects (who are smartphone users) according to sample size calculation will be selected randomly to complete the neck disability index and visual functional questionnaire 25 version 2000

Eligibility criteria:
inclusion criteria: * 141 subjects who are smartphone users * age between 18 to 50 years * both genders are included * subjects who put in more than 4 hours a day using smartphone * participants without systemic illnesses or physical deformities were also included * consent: participants who provide informed consent to participate in the study. * neck disability index will be used to assess how your neck pain has affected your ability to manage in everyday life. * visual functioning questionnaire version 2000 will be used to assess vision-related quality of life exclusion criteria: * people with head and neck injuries * eye diseases * people with diabetic retinopathy * who had refractive correction surgery * psychiatric problems (depression) * people with systemic illnesses or physical deformities * people who have vision impairments and disabilities

Keywords: neck pain vision smartphone
effect of aspirin at the acute phase of cerebral ischemic event.

Conditions: Ischemic Stroke

Summary: aspirin is the only anti-platelet medication used at the acute phase of ischemic stroke. the investigators would like to study laboratory effect of the first oral 300 mg dose of aspirin, given at hospital, after an ischemic event. the principal hypothesis is that platelet activity would be able to recover during this day and could lead to ischemic recurrences. two blood samples are accomplished. the first 2 hours after aspirin intake and the second 23 hours after. photometric aggregometry are performed with arachidonic acid and collagen induced platelet aggregation, measure of thromboxan b2 levels and reticular platelets count.


Eligibility criteria:
inclusion criteria: * adult men and women * ischemic stroke less than 48 hours * signed consent exclusion criteria: * danger to prescription of aspirin (haemorrhagic risk...) * prescription of heparin or vka

Keywords: aspirin platelet
acute effects of preladenant (sch 420814) on dyskinesia and parkinsonism in levodopa treated participants (p05550)

Conditions: Parkinson Disease

Summary: this is a randomized, placebo-controlled, 3-period crossover, balanced, single-site, third party-blind study of preladenant (sch 420814) in participants with parkinson disease (pd) to be conducted in conformance with good clinical practices. this trial will investigate the effects of single doses of preladenant and placebo on the dyskinesia and antiparkinsonian actions of a levodopa infusion. the study will examine 10 mg ("low dose") or 100 mg ("high dose") study drug, given as single, oral administrations in conjunction with intravenous (iv) levodopa infusion and oral carbidopa.


Eligibility criteria:
inclusion criteria: * participant must have a diagnosis of idiopathic pd based on history, exam and any relevant laboratory tests * participants must have been treated with levodopa for one or more years * participants must have motor fluctuations that can be measured as a 10% change in tapping speed between "on" and "off" and concurrent motor unified pd rating scale (updrs) must also show a 20% improvement when "on" * participants must have dyskinesia when "on" measured as at least 2 in one or more body parts on scale using 0 (absent) to 4 (severe) for four limbs, trunk, neck and face (total 7 body parts and 28 points) * participant must be free of any clinically significant disease that would interfere with the study evaluations * female participants must be postmenopausal and/or surgically sterilized and have a negative serum pregnancy test at the screening visit and a negative urine or serum pregnancy test upon each admission to the study center * premenopausal, unsterilized female participants have to agree to use a medically accepted method of contraception * male participants must agree to use a medically accepted method of contraception as or abstain from sexual intercourse during the trial and for 2 months after stopping the medication. exclusion criteria: * female participants who are pregnant, intend to become pregnant (within 3 months of ending the study), or are lactating * participants with dementia (mini-mental state examination \[mmse\] \<23), hallucinations, confusion, major psychiatric disorders, and unstable medical conditions * participants with any stable surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug * participants with a positive screen for drugs of abuse * participants who are positive for hepatitis b surface antigen, hepatitis c antibodies or human immunodeficiency virus (hiv) * participants who are currently participating in another medical interventional clinical study or have participated in a medical interventional clinical study within 30 days and who have previously received this compound.
the impact of overnight nutrition support on sleep and circadian rhythm disruption in the icu

Conditions: Feeding Patterns; Sleep; Glucose Intolerance

Summary: the purpose of this study is to determine whether modifying the timing of nutrition support from overnight to daytime enhances sleep quality, preserves circadian rhythms, and improves overall inflammation and cardiometabolic profiles in postoperative patients in the cardiac surgical icu on enteral nutrition.

intensive care unit (icu) environments do not support sleep or preserve circadian rhythms of postoperative critically ill patients. among the contributing factors is the common practice of administering nutrition support through feeding tubes overnight. the overall objective of the study is to examine a novel dimension of clinical nutrition by determining whether enhancing sleep quality and preserving robust circadian rhythms through daytime instead of overnight feeds will attenuate inflammation and improve cardiometabolic profiles of postoperative cardiac icu patients on nutrition support. the investigators hypothesize that overnight nutrition support results in fragmented sleep and blunted circadian rhythms and thus represent a modifiable mechanism exacerbating inflammation and cardiometabolic derangements in postoperative cardiac patients. results of this study will help in the development of evidence-based, cost-efficient, and effective enteral nutrition timing countermeasures against fragmented sleep, disrupted circadian rhythms, inflammation and cardiometabolic derangements and potentially modify the current widespread practice of overnight nutrition likely affecting 250,000 hospital admissions annually in the united states.

Eligibility criteria:
inclusion criteria: * adult male or non-pregnant female volunteers (age 18+) * scheduled for a cardiac surgical procedure with planned post-operative admission to the icu for \>48 hours * able and willing to give consent and comply with study procedures exclusion criteria: * blind, deaf or unable to speak english * women who are pregnant or nursing * contraindications to safe use enteral nutrition, including gastrointestinal obstruction * personal history of intestinal malabsorption, gallbladder disease or pancreatitis * dietary restrictions precluding enteral feeds * renal and liver failure requiring dialysis or child-pugh score \> 7 * severe deficit due to structural or anoxic brain damage * with skin condition that precludes wearing sensors

Keywords: enteral nutrition chrononutrition intensive care unit chronobiology nutrition support sleep
a study of effect of selpercatinib (ly3527723) in participants with normal and impaired renal function

Conditions: Healthy; Renal Insufficiency

Summary: the main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. the study will last up to 9 days, excluding screening.


Eligibility criteria:
inclusion criteria: for all participants: * body mass index (bmi) ≥ 18.0 and ≤ 40.0 kilograms per meter squared (kg/m²) and had a minimum weight of at least 50 kg at screening * have normal blood pressure, pulse rate, electrocardiogram (ecg), and blood and urine laboratory test results that are acceptable for the study * female of non childbearing potential: must have undergone sterilization procedures at least 6 months prior to the screening * males who are capable of fathering a child must agree to use contraception from the time of the dose administration through 6 months after the last dose for renal participants: * participant has stable renal disease status and function at least 1 month prior to loxo-292 administration. * participant is not currently or has not previously being on hemodialysis * baseline estimated glomerular filtration rate (egfr) based on the modification of diet in renal disease (mdrd) equation at screening as follows: * severe renal impairment (ri): \< 30 milliliter per minute (ml/min)/1.73m² * moderate ri: ≥ 30 and \< 60 ml/min/1.73m² * mild ri: ≥ 60 and \< 90 ml/min/1.73m² the mdrd equation is as follows (for females multiply result by 0.742, if african american multiply result by 1.212): egfr = 175 x \[serum creatinine in milligrams per deciliter (mg/dl) measured with a standardized assay\]\^-1.154 x (age)\^-0.203 exclusion criteria: for renal participants: * has rapidly fluctuating renal function, as determined by historical measurements; or has demonstrated or suspected renal artery stenosis. rapidly fluctuating renal function is defined as creatinine clearance or egfr that differs by more than 20% within at least 3 months of the screening creatinine clearance or egfr. if historical measurements are not available, then the 2 screening measurements will be used to demonstrate stability. * participants who have had a renal transplant, a nephrectomy, or participants with a known history of nephrotic syndrome. * participants who have required new medication for renal disease within 30 days prior to check-in
treatment of multifocal lung adenocarcinoma

Conditions: Lung Neoplasms; Carcinoma Non-small-cell Lung; Adenocarcinoma

Summary: to gather preliminary safety and outcome data for the multimodality treatment of lung adenocarcinoma in the setting of multifocal bac.

lung bronchoalveolar carcinoma (bac) or adenocarcinoma in situ (ais) continues to represent a poorly understood clinical entity. a frequent clinical dilemma in lung cancer care is the management of a documented or suspected invasive adenocarcinoma in the setting of multifocal ground glass opacity (ggo) consistent with multifocal ais. these patients are typically classified as stage iv disease, and treated with palliative chemotherapy. no existing pathologic or molecular test is currently capable of making the distinction between independent primary versus metastatic tumors, a distinction for which substantial treatment impact exists. many treating physicians suspect that outcomes for this specific patient subgroup are better than norms for stage iv disease, as such patients are frequently node-negative and without distant metastases despite multiple lesions present. to address this issue, we will evaluate a multimodality treatment protocol using aggressive local and targeted systemic therapy for multifocal lung adenocarcinoma, incorporating information from tumor genome sequencing for individualized treatment planning. the results will have significant impact in advancing the biologic understanding and treatment approach for lung adenocarcinoma in the setting of multifocal ais.

Eligibility criteria:
* patient must be \> 18 years of age * two or more ggo's or solid lesions suspicious for multifocal disease. * clinical diagnosis of n0 * no evidence of distant metastases * no prior intra-thoracic radiation therapy (note: previous radiotherapy as part of treatment for head and neck, breast, or other non-thoracic cancer is permitted.), previous chemotherapy, or surgical resection for non-small cell lung cancer (nsclc). * no other cancer in the past 5 years except early stage prostate cancer, or basal cell of skin. * pft's that show patient is capable of tolerating a lung resection. * non-pregnant and non-lactating. women of child-bearing potential must have a negative urine or serum pregnancy test to participate in the study. * patient must be able to understand and willing to sign an irb-approved informed consent document.

Keywords: multifocal genetic bronchoalveolar carcinoma adenocarcinoma in situ ground glass opacity next generation sequencing
surveillance of influenza virus among children with febrile respiratory complaints attending the pediatric clinic of the first affiliated hospital, shantou university medical college, shantou, guangdong, mainland china

Conditions: Influenza Type A; Influenza Type B

Summary: the surveillance of influenza virus among children with febrile reparatory complaints attending the pediatric clinic in shantou is an epidemiologic study to identify the type (influenza a or b) and the subtype of influenza a of the isolates from children with febrile respiratory complaints who attend the pediatric clinic of the first affiliated hospital, shantou university medical college, shantou guangdong, china. also this study investigates the genetic composition of all segments of isolated strains using standard molecular techniques and to make available the new strains of influenza viruses isolated from such children for the formulation of influenza vaccines. clinical manifestation of the respiratory illness is recorded and single nasopharyngeal swab is obtained from eligible children. viral culture is performed on the nasopharyngeal secretions. if influenza is isolated, this is characterized if it belongs to influenza a or b. if the virus is characterized as influenza a, further antigenic studies is done to determine subtype of influenza. viral isolates is further studied to determine the genetic composition of the virus. information obtained from the viral isolates is shared with the who and the cdc.

objectives primary objective: * to identify the type (influenza a or b) and the subtype of influenza a of the isolates from children with febrile respiratory complaints who attend the pediatric clinic of the first affiliated hospital, shantou university medical college, shantou, guangdong, china. secondary objectives * to investigate the genetic composition of all segments of isolated strains using standard molecular techniques. * to make available the new strains of influenza viruses isolated from such children for the formulation of influenza vaccines.

Eligibility criteria:
inclusion criteria: * age: 0 day to 18 years. * patient was seen at the pediatric clinic of the first affiliated hospital within 7 days of the onset of signs and symptoms of febrile respiratory illness suspected to be of viral origin (temperature \> 37.7ºc or reliable history of fever before being examined, and respiratory symptoms and signs such as cough, sore throat, and coryza). * parents agree to a nasopharyngeal specimen being taken by swab from their child. exclusion criteria: * patient is too ill to tolerate a nasopharyngeal specimen swab.
effects of change in blood pressure on retinal capillary rarefaction in patients with arterial hypertension

Conditions: Arterial Hypertension; Blood Pressure, High

Summary: to evaluate whether in patients with initially poorly-controlled arterial hypertension, structural and functional differences in the retina and choroid remain after achieving a well-controlled blood pressure.

optical coherence tomography angiography (oct-a) is an ocular imaging technique which allows fast and non-invasive assessment of the retinal microvasculature. with the oct-a, a reduction in capillary density in patients with arterial hypertension has been found. in animal experiments, this so called retinal capillary rarefaction could be reversed after administration of antihypertensive medication. the main aim of the present study is to evaluate whether in patients with initially poorly-controlled hypertension, an increase in capillary density can be demonstrated, if patients achieve well-controlled blood pressure with antihypertensive medication. in addition changes in retinal oxygen metabolism and choroidal blood flow will be investigated.

Eligibility criteria:
inclusion criteria: * men and women aged ≥ 18 years * signed informed consent * apart from hypertensive retinopathy, normal ophthalmic findings * non-smokers * patients with initially diagnosed or pre-existing mild to moderate primary arterial hypertension (systolic office blood pressure ≥ 140 mmhg and/or diastolic office blood pressure ≥ 90 mmhg) * planned initiation of antihypertensive medication or planned adaption of antihypertensive medication by the department of cardiology * subject agrees to perform regular blood pressure self-measurements and to document blood pressure values in a diary exclusion criteria: * participation in a clinical trial in the three weeks preceding the study * blood donation in the three weeks preceding the study * symptoms of a clinically relevant illness in the three weeks preceding the study * history of family history of epilepsy * secondary hypertension (e.g.: hyperaldosteronism, pheochromocytoma, renal artery stenosis, renal parenchymal diseases, cushing-syndrome, coarctatio aortae) * history of hypertensive encephalopathy or intracerebral bleeding * diabetes mellitus type 1 or type 2 * pregnant or breast-feeding women * women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception

Keywords: retinal capillary rarefaction hypertension antihypertensive medication oct-a retinal oxygen extraction choroidal vascularity index (cvi) ocular blood flow